Compugen Ltd. (NASDAQ:CGEN) Stock Has Consensus Price Target of $5.00 According to Brokerages

Shares of Compugen Ltd. (NASDAQ:CGEN) have received a consensus rating of “Buy” from the five ratings firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $5.00.

CGEN has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $4.00 target price on shares of Compugen in a research note on Monday, October 12th. Weiss Ratings raised shares of Compugen from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Wednesday, August 5th.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Platform Technology Partners increased its stake in shares of Compugen by 10.0% in the 1st quarter. Platform Technology Partners now owns 55,000 shares of the biotechnology company’s stock valued at $117,000 after buying an additional 5,000 shares during the period. Glenmede Trust Co. NA raised its stake in shares of Compugen by 187.5% during the first quarter. Glenmede Trust Co. NA now owns 34,500 shares of the biotechnology company’s stock worth $73,000 after buying an additional 22,500 shares during the last quarter. Calamos Advisors LLC bought a new stake in shares of Compugen during the first quarter worth approximately $63,000. Hillsdale Investment Management Inc. acquired a new position in Compugen in the first quarter valued at approximately $68,000. Finally, WINTON GROUP Ltd lifted its holdings in Compugen by 26.0% in the second quarter. WINTON GROUP Ltd now owns 197,110 shares of the biotechnology company’s stock valued at $422,000 after buying an additional 40,614 shares during the period. 12.22% of the stock is currently owned by institutional investors.

Compugen Stock Performance

Shares of NASDAQ:CGEN opened at $1.96 on Friday. Compugen has a twelve month low of $1.43 and a twelve month high of $3.23. The firm has a market cap of $185.32 million, a PE ratio of 5.16 and a beta of 2.78. The business has a fifty day moving average of $2.38 and a 200-day moving average of $2.43.

Compugen (NASDAQ:CGEN) last released its quarterly earnings results on Monday, August 3rd. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. Compugen had a return on equity of 42.57% and a net margin of 47.56%. The business had revenue of $2.60 million during the quarter, compared to analysts’ expectations of $1.28 million. During the same period in the previous year, the business posted ($0.08) earnings per share. On average, analysts anticipate that Compugen will post -0.28 EPS for the current fiscal year.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage biotechnology company focused on developing therapeutics for cancer and other diseases involving the immune system. The company uses computational biology and artificial intelligence-driven approaches to identify potential drug targets and develop antibody-based immunotherapies designed to restore or enhance the immune system’s ability to recognize and attack tumors.

Compugen’s pipeline has included investigational immune checkpoint and immuno-oncology programs, including COM701, an antibody targeting PVRIG, and COM902, an antibody targeting TIGIT.